Rocket Pharmaceuticals (RCKT) PT Raised to $15 at Cantor Fitzgerald
Tweet
Share
E-mailGet Alerts RCKT Hot Sheet
Price: $2.75 +3.38%
Rating Summary:
15 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Rating Summary:
15 Buy, 7 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Join SI Premium – FREE
Cantor Fitzgerald analyst Josh Schimmer raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $15.00 (from $10.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Rocket Pharmaceuticals completes $180 million priority review voucher sale
- Adobe (ADBE) PT Lowered to $379 at Bernstein SocGen Amid 'Increased Uncertainties'
- Gartner (IT) PT Lowered to $164 at UBS on Q2 Outlook
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
